Thanks ymav4294,
what I mean is, once progression has occured they may remain in an expanded trial group. Since they will accumulate a cohort under the CANVAS trial it would be silly, and I don't think Prima's intention, to return this group to SOC. If that happens the funding needs should be fairly minimal as funding is in place up to 156 weeks anyway. Time will tell. I think Prima should address this aspect in the form of a newsletter or announcement.
interim data from can-003 clinical trial, page-20
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.3¢ |
Change
0.003(0.86%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.5¢ | 28.8¢ | $31.26K | 107.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 190640 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 73165 | 12 |
View Market Depth
| Last trade - 10.26am 07/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |